4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding 4D Molecular Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 64 | 56 | −8 |
| Shares | 15.4M | 16.6M | +1.23M (+8.0%) |
| Value | $664.8M | $400.0M | −$264.8M (−39.8%) |
New holders (10)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jacobs Levy Equity Management, Inc | 37,417 | $901.0K | 0.01% |
| Swiss National Bank | 20,600 | $496.0K | 0.00% |
| Walleye Capital LLC | 12,205 | $294.0K | 0.01% |
| SG Americas Securities, LLC | 9,265 | $223.0K | 0.00% |
| State of Wisconsin Investment Board | 8,786 | $212.0K | 0.00% |
| Vident Investment Advisory, LLC | 8,521 | $205.0K | 0.01% |
| Virtus ETF Advisers LLC | 7,642 | $184.0K | 0.08% |
| Advisor Group Holdings, Inc. | 5,875 | $141.0K | 0.00% |
| Signaturefd, LLC | 86 | $2.00K | 0.00% |
| US Bancorp | 20 | $0 | 0.00% |
Sold out (18)
Institutions that held 4D Molecular Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| SB Management Ltd | 347,910 | $15.1M |
| Price T Rowe Associates Inc | 279,746 | $12.1M |
| Cormorant Asset Management, LP | 200,000 | $8.68M |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 157,500 | $6.83M |
| Deerfield Management Company, L.P. (Series C) | 150,000 | $6.51M |
| Ally Bridge Group (NY) LLC | 150,000 | $6.51M |
| Wellington Management Group LLP | 90,251 | $3.91M |
| TD Asset Management Inc | 27,448 | $1.19M |
| UBS Group AG | 20,592 | $893.0K |
| Acuta Capital Partners, LLC | 20,000 | $868.0K |
| Marshall Wace, LLP | 18,760 | $814.0K |
| Goldman Sachs Group Inc | 12,486 | $542.0K |
| Capstone Investment Advisors, LLC | 5,879 | $255.0K |
| Caas Capital Management LP | 5,000 | $217.0K |
| MetLife Investment Management | 4,083 | $177.1K |
| Metropolitan Life Insurance Co | 2,984 | $129.4K |
| STRS Ohio | 1,900 | $82.0K |
| Bank of Montreal | 244 | $10.0K |